



PRESS RELEASE

December 1, 2023

Ziccum to present at 'Inhaled Biologics' live webinar with KOL Assoc Prof. Per Gerde

On Monday Dec 11 Ziccum presents as special guest at a live scientific webinar on 'Inhaled Biologics' with inhalation Key Opinion Leader Assoc. Prof. Per Gerde. New Ziccum COO Xavier Turon will present the company at the webinar, which addresses formulation scientists working on new, more stable formulations of biopharmaceuticals.

Register for the Webinar [here](#).

The webinar will cover:

- i. how LaminarPace, Ziccum's Mass Transfer technology, uniquely formulates and dries biologics, without exposing them to extreme temperatures, as stable, bioactive dry powders that are highly suited for inhalation
- ii. Preclinical Testing solutions for Inhalable Formulations.

The Webinar is part of a series for industry developers hosted by Inhalation Sciences AB. This session, part of that series, is titled "INHALED BIOLOGICS: Realization and Preclinical Testing of Dry Powder Formulations".

Inhalable solid dose forms of biologics including next-generation mRNA vaccines are of great interest to the biopharmaceutical industry at the moment, promising increased storage stability, simplified patient administration and an ability to stimulate the mucosal immune system. LaminarPace was originally developed by Associate Professor Gerde specifically to dry liquid biologics for inhalation.

For more information about Ziccum, please contact:

Ann Gidner,
CEO Ziccum
Mail: gidner@ziccum.com
Mobile: +46 722140141

Fredrik Sjövall,
Chairman of the Board, Ziccum AB
Mail: sjovall@ziccum.com
Mobile: +46 706 45 08 75

Ziccum's Certified Adviser is
Carnegie Investment Bank AB (publ).
Follow us on <https://eucaps.com/ziccum>

About Ziccum

Ziccum is developing LaminarPace™, a unique drying method for biopharmaceuticals and vaccines based on mass transfer, not heat transfer. The technology is offered by licensing to vaccine and biologics developers and manufacturers in the global pharmaceutical industry. By reducing drying stress to the active ingredient, LaminarPace™ uniquely enables particle-engineered, thermostable dry powder biopharmaceuticals which can be easily handled and transported and are highly suitable for novel administration routes. The technology has been successfully applied to mRNA, peptides, proteins, antibodies, lipids and enzymes as well as excipients and adjuvants, and is well suited for industrial application. Ziccum is listed on the Nasdaq First North Growth Market.

Attachments

[Ziccum to present at 'Inhaled Biologics' live webinar with KOL Assoc Prof. Per Gerde](#)